Tocilizumab for treating severe COVID-19 pneumonia refractory to
combined hydroxychloroquine, lopinavir plus ritonavir and favipiravir:
case series
- Manoon Surabotsophon,
- Yingyot Klai-On,
- Vipa Thanachartwet,
- Sirote Khunapornphairote,
- Supat Chamnanchanunt,
- Theerapat Racharak,
- Wannada Laisuan,
- Duangjai Sahassananda,
- Samlee Hapunna,
- Somjit Jinapuk,
- Suthee Leelasetakul,
- Varunee Desakorn
Wannada Laisuan
Mahidol University Faculty of Medicine Ramathibodi Hospital
Author ProfileAbstract
Three patients with COVID-19 pneumonia received treatment with
hydroxychloroquine combined with lopinavir plus ritonavir and
favipiravir. Two patients early diagnosed with COVID-19 pneumonia
received tocilizumab at severe pneumonia diagnosed and survived. The
third patient was late diagnosed and received tocilizumab when the
disease progressed to ARDS, and passed away.17 Jul 2020Submitted to Clinical Case Reports 20 Jul 2020Submission Checks Completed
20 Jul 2020Assigned to Editor
23 Jul 2020Reviewer(s) Assigned
30 Jul 2020Review(s) Completed, Editorial Evaluation Pending
30 Jul 2020Editorial Decision: Revise Minor
04 Sep 20201st Revision Received
05 Sep 2020Submission Checks Completed
05 Sep 2020Assigned to Editor
05 Sep 2020Review(s) Completed, Editorial Evaluation Pending
08 Sep 2020Editorial Decision: Accept
